Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Eukaryotic translation initiation factor 2a kinase 3 (EIF2AK3; PERK)

Primary tumor, cell culture and mouse studies suggest PERK inhibitors could help treat breast cancer. In primary breast tumors and in human breast cancer cell lines, markers of epithelial-to-mesenchymal transition (EMT) were associated with upregulation of the PERK signaling pathway. In human breast cancer cell lines that underwent EMT, a research compound that inhibited PERK decreased cell growth and migration compared with vehicle. In mice injected with a metastatic mammary cancer cell line, pretreatment with the PERK inhibitor decreased tumor burden in the lungs compared with vehicle pretreatment. Next steps could include testing the PERK inhibitor in additional tumor types.

SciBX 7(18); doi:10.1038/scibx.2014.516
Published online May 8, 2014

Patent and licensing status unavailable

Feng, Y. et al. Cancer Discov.; published online April 4, 2014;
doi:10.1158/2159-8290.CD-13-0945
Contact: Piyush B. Gupta, Whitehead Institute for Biomedical Research, Cambridge, Mass.
e-mail:

pgupta@wi.mit.edu